Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Thermo Fisher Scientific to Divest Microbiology Business to Astorg for $1.075 Billion – Strategic Portfolio Optimization

Fineline Cube Apr 28, 2026
Company Deals

Aureka Biotechnologies Secures $35M Series A+ Financing to Advance AuraIDE Platform for Functional Antibody Design

Fineline Cube Apr 28, 2026
Company Deals

Hangzhou’s Adcoris Licenses First-in-Class 5T4-Targeting ADC ACR246 to U.S. Biotech K2 Therapeutics in Deal Worth Up to $730 Million

Fineline Cube Apr 27, 2026
Company Deals

Sino Biopharmaceutical’s Chia Tai Tianqing and Shanghai Reunion Partner to Commercialize Respacio Hydrogel for Cervical Cancer Radiotherapy Protection in China

Fineline Cube Apr 27, 2026
Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Fineline Cube Apr 28, 2026
Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Fineline Cube Apr 28, 2026
Company Deals

WuXi ATU Licenses TESSA Technology to Janssen Biotech for AAV Production

Fineline Cube Aug 12, 2022

WuXi Advanced Therapies (WuXi ATU), the gene and cell therapy-focused CTDMO unit of WuXi Apptec,...

Company Deals

Medlander Medical Technology’s IPO Raises RMB 1 billion on Shanghai’s STAR Board

Fineline Cube Aug 12, 2022

Medlander Medical Technology Inc., a leading Chinese manufacturer of pelvic floor rehabilitation equipment, has completed...

Company Drug

InnoCare Pharma’s Orelabrutinib sNDA Accepted for Marginal Zone Lymphoma

Fineline Cube Aug 12, 2022

InnoCare Pharma (HKG: 9969) announced that a supplemental New Drug Application (sNDA) for its Bruton’s...

Company Deals

TianShiWei Raises Tens of Millions in Series A for Medical Aesthetics Expansion

Fineline Cube Aug 12, 2022

hina-based Wuhan TianShiWei Biotechnology Co., Ltd has reportedly raised tens of millions of renminbi in...

Company Deals

BeiGene Partners with Jilin Cancer Hospital for Cancer Drug Development

Fineline Cube Aug 12, 2022

China-based BeiGene (NASDAQ: BGNE, HKG: 6160, SHA: 688235) has entered into a clinical study partnership...

Policy / Regulatory

China Ramps Up Monitoring of Clinically Shortage Drugs Involving 109 Varieties

Fineline Cube Aug 12, 2022

The Ministry of Industry and Information Technology (MIIT), National Health Commission (NHC), National Healthcare Security...

Company Drug

Arbele’s ARB202 Enters Phase I Trial for Advanced Gastrointestinal Cancer

Fineline Cube Aug 11, 2022

Hong Kong-based biopharma Arbele announced that its CDH17 × CD3 bispecific T-Cell engager antibody, ARB202,...

Deals Hospital

ByteDance Acquires Amcare Healthcare for USD1.5b via Xiaohe Health Unit

Fineline Cube Aug 11, 2022

ByteDance Ltd, the parent company of social media platforms TikTok and Douyin, has acquired Amcare...

Company Deals Legal / IP Policy / Regulatory

Taihu Bay Healthcare Conference Launches Wuxi IP Protection Center

Fineline Cube Aug 11, 2022

The 2022 Taihu Bay Future Healthcare Conference was held in Wuxi City, Jiangsu province, China,...

Company Deals

United Imaging Healthcare’s STAR Listing Raises USD1.85 Billion

Fineline Cube Aug 11, 2022

Shanghai-based United Imaging Healthcare (UIH) has completed an initial public offering (IPO) of 100 million...

Company Medical Device

Boston Scientific’s Rezūm System Installed in China’s Urinary Innovation Center

Fineline Cube Aug 11, 2022

US major Boston Scientific Corporation (NYSE: BSX) has jointly established the “Urinary Joint Innovation Center”...

Company Deals

Trautec Medical Raises RMB200m in Series A Financing for Recombinant Collagen R&D

Fineline Cube Aug 11, 2022

China-based Jiangsu Trautec Medical Technology Co., Ltd. has reportedly raised nearly RMB200 million (USD205.3 million)...

Drug

Zhaoke Ophthalmology Enrolls First Patient in ZKY001 Phase II TPRK Study

Fineline Cube Aug 11, 2022

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) spin-off Zhaoke Ophthalmology Ltd (HKG: 6622) announced the...

Company Deals

Insilico Medicine Closes USD95m Series D Financing to Advance AI Drug Discovery

Fineline Cube Aug 11, 2022

Insilico Medicine, a Hong Kong-based artificial intelligence (AI)-driven drug discovery company, announced the closure of...

Company Drug

LianBio Completes Enrollment for Mavacamten Phase III Trial in oHCM

Fineline Cube Aug 11, 2022

China-based biotech LianBio (OTCMKTS: LIANY) announced that enrollment has been completed in the Phase III...

Company Deals

Huadong Medicine to Acquire 60% Stake in Wuhu Huaren for RMB 396 Million

Fineline Cube Aug 11, 2022

China-based Huadong Medicine Co., Ltd (SHE: 000963) announced that its subsidiary, Hangzhou Zhongmei Huadong Pharmaceutical...

Company Drug

Recbio Completes Enrollment for HPV Vaccine REC603 Immuno-Bridging Study

Fineline Cube Aug 11, 2022

China-based vaccine maker Jiangsu Recbio Technology Co., Ltd (HKG: 2179) announced the completion of subject...

Company Deals Drug

Everest Medicines’ Xerava NDA Accepted by Taiwan’s TFDA

Fineline Cube Aug 11, 2022

Everest Medicines (HKG: 1952) announced that its New Drug Application (NDA) for Xerava (eravacycline) for...

Company

China Grand Pharma’s H1 2022 Revenues Up 14.1% to USD664m, R&D Spending Rises

Fineline Cube Aug 11, 2022

China Grand Pharmaceutical and Healthcare Holdings Ltd (HKG: 0512) published its financial results for the...

Company Drug

HutchMed and AstraZeneca’s Tagrisso-Orpathys Combo Shows Promise in NSCLC Study

Fineline Cube Aug 10, 2022

Hutchison China Meditech (HutchMed; NASDAQ: HCM, HKG: 0013) and AstraZeneca (AZ, NASDAQ: AZN) announced the...

Posts pagination

1 … 630 631 632 … 658

Recent updates

  • Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform
  • Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise
  • AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise
  • GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development
  • Prothena’s Coramitug Receives FDA Fast Track Designation for ATTR-CM – Advancing Novo Nordisk’s $1.2B Amyloidosis Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Drug

Santo Therapeutics Secures Dual FDA Designations for ST002 Gene Therapy in NF2-Related Schwannomatosis – Advancing In Vivo Lentiviral Platform

Company Drug

Johnson & Johnson’s Imaavy (nipocalimab) Receives FDA Priority Review for Warm Autoimmune Hemolytic Anemia – Expanding FcRn Blocker Franchise

Company Drug

AbbVie Submits FDA Filing for Skyrizi Subcutaneous Induction Therapy in Crohn’s Disease – Expanding IL-23 Inhibitor Franchise

Company Drug

GSK’s Efimosfermin Receives Dual Regulatory Designations for MASH Treatment – Breakthrough Therapy and PRIME Status Support Phase III Development

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.